Interim report
Page 1
Interim Report April – September 2026 ”The focus is on emerging from the tough period stronger and ready for the next growth phase.” Axel Schörling CEO EQL Pharma AB (publ) 0.4 RESULT PER SHARE FOR THE PERIOD 46 PRODUCTS IN PIPELINE 2 added during Q2 49 PRODUCTS 0 launched during Q2 SEK Millions 52.4 CASH, AT THE END OF PERIOD Figures in parentheses refer to the same period last year. MSEK Jul – Sep 2026 Jul – Sep 2025 Apr – Sep 2026 Apr – Sep 2025 Apr 2025 – Mar 2026 Net sales 157.2 86.4 26 4 .1 193.6 432.7 Sales growth % 82 1 36 15 16 Gross profit 56.2 32.4 74 .1 78.6 162.8 Gross margin % 36 38 28 41 38 Operating profit (EBIT) 22.4 3.6 8.8 24.0 48.7 Operating margin (EBIT) % 14 4 3 12 11 Profit for the period 11.8 -3.4 -5.0 6.5 12.5 EBITDA 29.9 8.9 24.0 34.8 71.8 EBITDA-margin % 19 10 9 18 17 LTM EBITDA 60.9 91.8* N/A N/A 71.8 LTM EBITDA-margin % 12 22* N/A N/A 17 *Pro-forma rolling 12-month EBITDA, calculated as if the Medilink product portfolio had been owned for the full period and based on transaction-date cost assumptions. (- 0.11) before dilution (78.3) SEK Millions INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 2
Comments from the CEO The second quarter of the 2026/27 financial year was a strong quarter. Net sales amounted to SEK 157.2 (86.4) million, corresponding to growth of 82%. Gross margin recovered from the first quarter to 36% (38%) despite write- down of receivables and inventory of SEK 15 million. EBITDA margin of 19% (10%) also recovered compared with Q1 and the previous year’s Q2. No products were launched and two were added to the pipeline. Mellozzan has been launched in Turkey and Memprex has been launched in France under the brand name Altaromin. In addition, marketing authorizations for the first three significant Specialty Generics products were obtained during the quarter. EQL is going through a transformation phase aimed at emerging from the tough period the company is still in and building a base for future growth. The sales forecast for the full year 2026/27 is growth of around 15%. Financial overview for the second quarter Net sales amounted to SEK 157.2 million, growth of 82% against a weak comparison quarter. The relatively high sales were driven by competitors being out of stock on a key product where EQL was able to supply the market, accumulated sales milestones for Mellozzan, and a generally better inventory position. The market shortage for the key product is assessed to be temporary. Adjusted for positive one-off effects in the quar- ter, underlying sales are assessed to be approxi- mately SEK 120 million. The continued review of the balance sheet, which was flagged in Q1, has resulted in write- downs of SEK 15 million. These relate to provisions for claims against suppliers, where we cannot currently assess the outcome, and for destruction of stock. We see no further write-down needs beyond ongoing provisions for destruction of stock and any pruning of projects or products as a result of the transformation work. Operating profit (EBIT) increased to SEK 22.4 (3.6) million and EBITDA margin to 19% (10%). OPEX increased by 17% to SEK 33.9 million. Cash and cash equivalents amounted to SEK 52.4 (78.3) million and the unutilized working capital facility to SEK 33.4 (30.2) million. CAPEX was SEK 8.3 (9.7) million and leverage 6.6x EBITDA, still above the target. Adjusted for nega- tive one-off items over the past three quarters, leverage was 3.7x. Leverage is expected to remain above the target during 2026/27 and then sta - bilize at lower levels, driven by EBITDA recovery. Financial targets and forecasts for the current financial year The sales forecast for the full year 2026/27 is growth of around 15%, below the long-term target of 30%, which remains in place for the time being. EQL is evaluating whether the tough period the company is going through will affect the possibilities of reaching the long-term targets. This work is ongoing and the company will revert when a conclusion has been reached, probably during the current financial year. The primary focus at present is on operational upgrading. The situation regarding delivery disruptions continues to look better for the rest of the year. If this persists, Q1 of the current year will remain the low point of EQL’s tough period. However, it is too early to sound the all clear, and a sustainable, long-term improvement depends entirely on the transformation program continuing to deliver structural improvements that make EQL ready for the next growth phase. Product launches and market dynamics No products were launched during the quarter and the portfolio therefore consists of 49 prod- ucts. We expect four additional launches during the financial year, but the forecast is uncertain. In Q1 the ambition was eight products, but four of them now look likely to be launched next financial year. Improving the launch process plays a central role in the transformation program. Two products were added to the pipeline, giving 46 products in total. As the company closely monitors liquidity, caution is applied with new signings until the tough period is over. At present, only products where the payment model for the rights is back-loaded are signed. Marketing authorizations for the first three Specialty Generics products with more signifi - cant potential were obtained during the quarter. The objective is for these to be launched next financial year. Thereafter it is estimated to take 2–3 years before they reach their full potential. For Memprex, Hungary has been added with the partner Pharmacenter. Launch volumes have been sold to our partner in France, but the product has not yet been placed on the market. For BeNeLux, marketing authorization has been obtained and launch preparations are ongoing. In Israel a launch is expected during the current financial year, and in Ireland registration is ongoing. For Mellozzan, EQL’s partner Abdi Ibrahim has launched in Turkey and a launch in Kazakhstan is expected later in the financial year. Launch prepa- rations are also ongoing in Italy, where a launch is expected next financial year. Applications are ongoing in the GCC and Ireland. Medice continues to increase sales, mainly in Germany and Swit- zerland, which triggered a first accumulated sales milestone to EQL. Discussions on further territo- ries are ongoing for both Mellozzan and Memprex. Other Although Q2 was a stronger quarter, and the outlook for Q3 and Q4 continues to look stable, it is too early to conclude that the tough period is behind us. The sharp growth of recent years and the addition of new products, suppliers and cus- tomers have created a complexity that requires an operational and organizational upgrade. The focus is on emerging from the tough period stronger andready for the next growth phase. We assess that the acute problem-solving phase is behind us and that the key right now is sustainable, struc- tural improvement of the company’s key pro- cesses to create a robust and scalable platform. Axel Schörling VD i EQL Pharma AB (publ) 2COMMENTS fr OM T hE CEO INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 3
Significant Events During the Quarter JULY 13TH 2026 Memprex© (methenamine hippurate) license signed with partner for Spain EQL’s key product Memprex© has now been licensed for sale in Spain with Gebro Holding GmbH (ltd), a leading local pharmaceutical company specialising in women’s health, gynaecology and urology. There is currently no product with methenamine hippurate offered in Spain. Memprex© offers an alternative for treatment of recurring urinary tract infections which is both non-inferior to long-term antibiotics and which doesn’t increase the risk to develop antibiotic-resistant bacteria since it is an antiseptic treatment rather than an antibiotic. JULY 15TH 2026 Mellozzan® (melatonin) approved in Kazakhstan EQL Pharma’s key product Mellozzan® (tablets) has been approved for sale in Kazakhstan. Approval has been obtained by EQL’s regional partner, Abdi Ibrahim. The approval currently covers the 3 mg strength. The Marketing Authorisation for the 5 mg strength is expected in December 2026. The launch of both strengths is expected in the fiscal year 2027/28. JULY 17TH 2026 Notice of Annual General Meeting in EQL Pharma AB The shareholders of EQL Pharma AB (Reg. No. 556713-3425) are hereby given notice of the Annual General Meeting to be held on Thursday, 20 August 2026, at 4:00 p.m. at the Company’s prem - ises at Stortorget 1, Lund. JULY 24TH 2026 EQL Pharma Annual Report 2025/26 The Company’s Annual Report is now available on the Company’s website. JULY 27TH 2026 EQL Pharma appoints Oskar Karmlid as new Chief Supply Chain Officer (CSCO) EQL Pharma has appointed Oskar Karmlid as its new Chief Supply Chain Officer (CSCO). Oskar will assume the role in October 2026, succeeding Martin Kristofferson, who is currently serving as Interim Head of Supply Chain. AUGUST 12TH 2026 Memprex© (methenamine hippurate) license signed with partner for Hungary EQL’s key product Memprex© has now been licensed for sale in Hungary with Pharmacenter, a leading local pharmaceutical com - pany specialising in orphan drugs, oncology, urology and hospital products in Hungary. AUGUST 20TH 2026 Bulletin from the annual general meeting in EQL Pharma AB on 20 August 2026 The annual general meeting resolved in accordance with the proposal from the Nomination Committee to re-elect Anders Månsson, Christer Fåhraeus, Linda Neckmar, Per Svangren and Raymond De Vré as members of the board of directors and to elect Niraj Kumar as new board member for the period until the end of the next annual general meeting. Christer Fåhraeus was re-elected as Chairman of the board of directors. The annual general meeting resolved in accordance with the proposal from the board of directors to implement a long-term incentive program for the company’s Chief Supply Chain Officer based on issue of warrants. The incentive program comprises a maximum of 100,000 warrants. Each warrant entitles the right to subscribe for one new share in the company at a subscription price per share corresponding to 200 per cent of the volume weighted average price according to Nasdaq Stockholm’s official price list for shares in the company during the ten trading days that follows immediately after the publication of the compa - ny’s interim report for April – June 2026. The warrants shall be issued to the fair market value of the warrants at the time of subscription, which shall be determined by Optionspartner as independent valuation institute in accordance with the Black & Scholes valuation formula. Subscription of shares by virtue of the warrants may be effected from and including 17 February 2031 to and including 3 March 2031. In case all warrants issued in con - nection with the incentive program are exercised for subscription of new shares, a total of 100,000 new shares will be issued, which corresponds to a dilution of approximately 0.34 per cent of the company’s share capital and votes. Events After the Quarter No significant events occurred after the end of the quarter. 3SIGNI fICANT E vENTS INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 4
Product Development EQL Pharma reports its product development pipeline on an aggregate basis. Individual products in development are generally not named until marketing authorization has been secured, and product-level market potential is not disclosed. The purpose is to give shareholders a clear view of pipeline progress while protecting commercially sensitive information. This report covers the first half of FY 2026/27, April-Sep - tember 2026, and reflects the position at the end of the reporting period. The information does not constitute financial guidance or a forecast of future revenue or earnings. The Quarter in Brief During the quarter, work continued across the development, review and launch phases. Major updates include the approval tacrolimus cap - sules, mycophenolate mofetil tablets and cap - sules, and everolimus tablets across our core markets of SE, DK, FI, and NO. This represents a major milestone for our Specialty business area In addition, EQL has received approval for its levodopa/benserazide tablets in Sweden. Products in Different Phases Development phase: This phase includes products developed by EQL Pharma together with external partners, as well as products for which the company has entered into licensing or distribution agreements for selected geographic markets. A product remains in this phase until the relevant regulatory application has been submitted. At the end of September, there were 30 products in EQL Pharma’s development pipeline. Review phase: Once development is complete, applications are submitted to the relevant regulatory authorities in the markets where the product is intended to be sold. The review process includes scientific, quality and administrative assessment and may involve requests for supplementary information. At the end of September, there were five products in the review phase as four products received marketing authorization, and we submitted applications for two products. Launch phase: Following regulatory approval, EQL Pharma prepares the product for commercial launch. Activities may include manufacturing and supply planning, reimbursement and pricing applications, tender participation, packaging and artwork, and coordination with distribution partners. In Q2 of FY26/27, EQL received marketing authorization for five new products (tacrolimus, mycophenolate mofetil tablets, mycophenolate mofetil capsules, everolimus, and levodopa/ benserazide). We expect to launch four additional products in the second half of this fiscal year, which is below our previous target of eight products. These launch delays have been caused by backlogs in partner laboratories in performing analytical methods transfer, and EQL Pharma is working to actively mitigate further risk. Products in Different Phases Pipeline and Launch Outlook Figure 1. Products by phase of development at the end of Q2 FY2026/27 Figure 2. Expected product launches by fiscal year based on management’s assessment at the end of Q2 FY 2026/27 Products under Development (30) Review Phase (5) Launch Phase (11)46 30 5 11 0 3 6 9 12 15 29/3028/2927/2826/27 6 Executed Planned 9 12 15 4PrODu CT DE vELOPMENT INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 5
EQL Pharma, through its partner Dr. Pfleger, launched methenamine hippurate (branded as Cystohipp® in Germany. Stock-up and launch preparations are also well underway with our commercial partners in France and BeNeLux for the introduction of methenamine hippurate throughout the rest of the fiscal year and the first period of 2027/28. Pipeline and Launch Outlook The timing of product launches is subject to uncertainty. Development, regulatory, man- ufacturing, reimbursement, tender and other commercial factors may bring launches forward, delay them or prevent them from taking place. The launch profile reflects management’s current assessment at the end of September FY 2026/27 and may change. It does not con - stitute financial guidance. EQL Pharma’s growth strategy is supported by new product launches and geographic expansion. The company primarily targets established molecules and formulations in mature markets where it believes it can build a competitive position. Our executed and planned FY26/27 launches include products for sale through our ‘traditional’ Nordic Pharmacy and Hospital channels, as well as entrants into new seg - ments Specialty (non-substitutable generics) and the German market. EQL sees growth in these new areas as crit - ical to our ongoing trajectory. More information on our business units and channel strategy can be found below. Marketed Products For reporting purposes, a product is defined by its unique active substance and/or formulation. Different formulations are treated as separate products, while the same product sold across several markets or pack sizes is treated as a single product. EQL Pharma currently markets 49 unique products. Geographic Markets EQL Pharma markets its portfolio directly under its own brand in the Nordics (SE, DK, NO, FI, and IS), along with a limited portfolio in Estonia, Latvia, Lithuania, Czechia, Austria and Portugal. In the rest of the world, our products are sold through our reputable network of com - mercial partners. Future expansion may use direct or partner-supported models, depending on regulatory requirements, market conditions and strategic fit. EQL Pharma regularly reviews their portfolio for opportunities to expand our footprint. Product Areas EQL Pharma develops and markets prescrip - tion medicines and rapid diagnostic tests across Pharmacy, Hospital, Tests, Brands and Specialty Generics. Marketed Products Figure 3. Marketed product portfolio by at the end of each fiscal year, and Q2 FY 2026/27. 0 10 20 30 40 50 FY 26/27FY 25/26FY 24/25FY 23/24 36 46 47 49 5PrODu CT DE vELOPMENT INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 6
Pharmacy: EQL Pharma’s core business unit, characterized by medicines that are dispensed at local pharmacies. Our strategy is to identify generic products that have been off patent for a long time, but given their market size have few competitors. We then work with partners to in-license or develop a new product These prod- ucts have stable volumes and are sold via direct substitution systems in the Nordics, providing a predictable business model with healthy margins, while delivering cost savings to health systems. Hospital: Similarly to the Pharmacy portfolio, EQL Pharma seeks to fill underserved niches for generic medicines administered in hospi - tals. This segment now makes up a meaningful proportion of EQL Pharma’s annual sales and provides stable and predictable revenue as products are sold via 1-2 year tenders. Brands: EQL Pharma’s branded portfolio is made up of Mellozzan (melatonin) and methenamine hippurate (brand name varies by market). While their active ingredients have been on the market for 20+ years, these prod - ucts are able to be sold as branded given their unique regulatory indications. Our branded portfolio has been, and is projected to remain, a meaningful driver of sales growth as we continue to expand our geographic presence – largely through commercial partners. Specialty: The Specialty portfolio is EQL Phar - ma’s newest strategic addition. These products are essentially a hybrid between standard generic medicine and branded products which require promotion. From a regulatory perspec - tive, the products are not patent protected but are not directly substitutable with other med - icines containing the same active ingredient. Instead, they provide attractive features such as a unique formulation, a narrow therapeutic window, or favorable price, which would cause a healthcare provider to write a prescription for the specific product. Limited promotion is required to drive growth, but not at the same intensity of traditional branded products. Tests: During the COVID-19 pandemic, the Tests portfolio made up a substantial portion of EQL Pharma’s sales and provided cash to invest entrance into the Hospital, Brands, and Specialty segments. However, under current market conditions, Tests are no longer a strate - gic focus of the company. 6PrODu CT DE vELOPMENT INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 7
Figure 5. Operating profit trend (EBIT) for fiscal year 2023/24 through the reporting period for the current fiscal year, the bars are EBIT and the line is rolling 12-month EBIT. The left Y-axis EBIT per quarter expressed in SEK million and the right Y-axis is rolling 12-month EBIT expressed in SEK million. Figure 4. Net sales trend fiscal year 2023/24 through reporting period for the current fiscal year. Left Y-axis quarterly turnover in SEK million. Right Y-axis rolling 12-months sales expressed in SEK million. * Excluding non-recurring sales until 2023/24 Quarterly Operating Profit (EBIT) and EBIT Rolling 12 months (R12)Quarterly Net Sales and Rolling 12 months (R12)* -15 -10 -5 0 5 10 15 20 25 Q2Q1Q4Q3Q2Q1Q4Q3Q2Q1Q4Q3 -20 -10 0 10 20 30 40 50 60 70 80 23/24 24/25 25/26 26/27 9,8 8,4 15,2 14,3 14,8 23,0 3,6 19,5 22,4 5,1 -13,6 20,5 30,4 32,6 40,0 47,7 52,8 67,4 72,6 61,9 66,5 48,7 14,6 33,4 0 30 60 90 120 150 180 210 Q2Q1Q4Q3Q2Q1Q4Q3Q2Q1Q4Q3 23/24 24/25 25/26 26/27 0 75 150 225 300 375 450 525 600 675 82% 70,2 78,1 82,8 85,2 92,2 113,3 107,2 86,4 118,9 120,2 106,9 157,2 Sales and Operating Profit Sales Development In the second quarter of the financial year 2026/2027, our net sales amounted to SEK 157.2 (86.4) million, which corresponds to a growth of 82%. Profit Performance Operating profit for the second quarter amounted to SEK 22.4 (3.6) million. The operating margin (EBIT) was 14% (4%). 7SALES AND OPE rATING PrOf IT INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 8
Cash Flow, Investments and Financing Gross Profit Gross profit increased by 74 percent to SEK 56.2 (32.4) million during the second quarter, which corresponds to a gross margin of 36 (38) percent. For the first half of the year, gross profit decreased by 6 per cent to SEK 74.1 (78.6) million, corresponding to a gross margin of 28 (41) per cent. The gross margin was affected by inventory adjustments, shipping costs, amorti - zation of capitalised development expenditure and currency effects. Cash flow Cash flow from operating activities before changes in working capital was positive at SEK 22.3 (1.1) million for the quarter. For the period April to September, the corresponding cash flow amounted to SEK 8.9 (18.9) million. Changes in working capital during the quarter amounted to SEK -17.1 (0.2) million. The change reflects a combination of reduced inventories and trade payables, as well as increased trade receivables. Changes in working capital for the period April to September amounted to SEK -14.0 (-20.7) million. The change reflects a combina - tion of reduced inventories and trade payables, as well as increased trade receivables. Total cash flow from operating activities amounted to SEK 5.2 (1.3) million for the quar - ter and SEK -5.1 (-1.9) million for the first half of the year. Investments EQL Pharma continues to invest in new prod - ucts. During the quarter, SEK 8.3 (9.7) million was invested in both ongoing and new projects. For the period April to September, invest - ments amounted to SEK 24.6 (33.2) million. Financing Cash flow from financing operations amounted to SEK -4.2 (30.0) million for the quarter. The outcome is affected to a timing difference attributable to customer payments having been received but had not yet been transferred from the factoring company to the Company’s bank account. For the period April to September, the corre - sponding figure was SEK -4.0 (35.9) million. Financial expenses Interest expenses attributable to loans amounted to SEK -7.6 (-7.8) million for the quar- ter. In addition to interest expenses on loans, financial expenses include interest on lease liabilities in accordance with IFRS 16. For the period April to September, interest expenses amounted to SEK -15.1 (-15.9) million. Financial position Cash and cash equivalents amounted to SEK 52.4 (78.3) million at the end of September, while the unutilised working capital credit facil - ity amounted to SEK 33.4 (30.2) million. Invoice financing and inventory financing facilities amounted to SEK 134 (134) million. Taxes Tax calculated at the applicable tax rate of 20.6 per cent amounted to SEK -3.1 (0.9) million for the quarter and SEK 1.3 (-1.7) million for the period April to September. 8SALES AND OPE rATING PrOf IT INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 9
Additional Information Parent Company EQL Pharma AB is the parent company of the EQL Pharma group. Net sales for the Parent Company during the second quarter amounted to SEK 157.2 (86.4) million. Operating profit totaled SEK 22,8 (3,6) million for the quarter and 9.2 (24.1) for the half-year. Personnel The number of full-time employees in the group is 25 (22), out of whom 15 (12) are women, at the Swedish parent company. In addition, the Group employs 40 (32) interna - tional employees, via a global platform for human resources management, who are mainly active in specialist functions and product and business development. In addition to the permanent staff, there are long-term consultants with expertise in GMP, pharmacovigilance, regulatory affairs, business development and wholesale operations tied to the parent company. Risk Factors This financial report includes statements that are forward looking but actual future results may differ materially from those anticipated. In addition to the factors discussed, the earnings can be affected by delays and difficulties in the various phases of development, such as formulation, stability, preclinical and clinical trials, but also potentially competition, eco - nomic conditions, patent protection and the exchange rate and interest rate fluctuations, and political risks. Several risk factors may have a negative impact on the operations of EQL Pharma. It is therefore important to consider the rele - vant risks alongside the Company’s growth opportunities. The following text describes risk factors in no particular order and with no claim to be exhaustive. Delays in launching new products can mean deterioration in earnings for the company and it cannot be excluded that the EQL Pharma in the future may need to raise additional capital. An aggressive investment strategy from competi - tion could pose risks in the form of slower sales and weaker profitability. Increased competi - tion could lead to negative sales and earnings effects for the Company in the future. External factors such as inflation, currency and interest rate fluctuations, supply and demand, booms and recessions as well as geo - political such as the unrest in the Middle East may have an impact on operating costs, freight costs, selling prices and equity valuations. EQL Pharma’s future revenues and valuation of shares may be adversely affected by these fac - tors, which are beyond the Company’s control. A large part of the purchases is made in euro whose value can change significantly. EQL Pharma will continue to develop new products in its field. Time and cost aspects of product development can be difficult to pre-de - termine with accuracy. This entails the risk that a proposed product is more costly than planned or takes longer than planned. Additional risks and uncertainties that are not currently known to EQL Pharma may be developed into important factors that affect the Company’s operations, results and financial position. For a more detailed list of risks, we refer to EQL’s Annual Report and Consolidated Financial Statement 2025/26, pages 45-47 and 61-62. Our Financial Goals For the new five-year plan, from 2024/25 to 2028/29, the goal is to grow by an average of 30%; stabilizing the EBITDA margin initially at around 25%; and at end of period above 25%. Our peak leverage shall be a maximum of 4.0x EBITDA, with a target at 2.5x. Sales growth for the current full year 2026/27 is forecast to around 15%. Upcoming reports Future reports for 2026/2027 will be published: FEB 4 2027 Interim r eport October - December 2026 (third quarter) MAY 5 2027 Year End report April 2026 - March 2027 (fourth quarter) 9ADDITIONAL INfOr MATION INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 10
Christer Fåhraeus Chairman Linda Neckmar Member Anders Månsson Member Per Svangren Member Raymond De Vré Member Niraj Kumar Member Board of Directors EQL Pharma Lund, November 4, 2026 The Auditors’ Review This interim report has been audited by the auditor. Questions Regarding the Interim Report For further information or questions, please contact: Axel Schörling President & CEO, EQL Pharma axel.schorling@eqlpharma.com +46 763 179 060 EQL Pharma is listed on Nasdaq Stock - holm, Small Cap list. The company is traded under the ticker symbol EQL and ISIN code SE0005497732. 10ADDITIONAL INfOr MATION INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 11
The Group Consolidated Profit and Loss Statement KSEK Note Jul – Sep 2026 Jul – Sep 2025 Apr – Sep 2026 Apr – Sep 2025 Apr 2025 – Mar 2026 Net sales 3 157,223 86,378 26 4 ,131 193,593 432,661 Cost of goods sold -100,983 -53,967 -190,055 -115,030 -269,819 Gross profit 56,241 32,411 74,076 78,562 162,842 Gross margin 36% 38% 28% 41% 38% Sales and marketing expenses -24,959 -19,780 -46,779 -37,387 -80,445 Administration expenses -4,878 -4,633 -10,771 -10,8 87 -22,479 r&D expenses -4,488 -4,509 -8,757 -7,335 -14,328 Other operating income 530 100 1,061 1,095 3,095 Operating profit (EBIT) 22,446 3,588 8,830 24,048 48,686 Other financial items 2 0 3 2 5 Interest paid -7,6 0 0 -7, 823 -15,082 -15,901 -30,487 Result before tax 14,848 -4,235 -6,249 8 ,149 18,205 Ta x -3,060 871 1,287 -1,68 4 -5,667 Net profit for the period 11,789 -3,364 -4,963 6,465 12,538 Other comprehensive income: Sum of other comprehensive income: 3 -1 4 3 2 Sum of Components to be reclassified to net profit: 3 -1 4 3 2 Sum of other comprehensive income: 3 -1 4 3 2 COMPREHENSIVE RESULT FOR THE PERIOD 11,792 -3,365 -4,959 6,468 12,540 11Th E Gr OuP'S S TATEMENTS INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 12
Per Share Data Per share data Jul – Sep 2026 Jul – Sep 2025 Apr – Sep 2026 Apr – Sep 2025 Apr 2025 – Mar 2026 Earnings per share, before dilution, SEK */ 0.40 - 0.11 - 0.17 0.22 0.42 Earnings per share, after dilution, SEK */ 0.40 - 0.11 - 0.17 0.22 0.42 Equity per share, SEK 8.88 8.80 8.88 8.80 9.04 Number of shares outstanding 29,529,610 29,529,610 29,529,610 29,529,610 29,529,610 Average number of shares outstanding, before dilution 29,529,610 29,529,610 29,529,610 29,529,610 29,529,610 Average number of shares outstanding, after dilution 29,529,610 29,949,610 29,529,610 29,949,610 3 0,169,610 Stock exchange rate, SEK 23.00 66.00 23.00 66.00 54.40 Dividend per share 0 0 0 0 0 * Based on the profit/loss for the period divided by the average number of shares in issue. Quarterly Earnings Trend KSEK Jul – Sep 2026 Apr – Jun 2026 Jan – Mar 2026 Oct – Dec 2025 Jul – Sep 2025 Net sales 157,223 106,908 120,167 118,902 86,378 Sales growth 82 0 6 29 1 Gross profit 56,241 17,836 33,989 50,291 32,411 Gross margin, % 36 17 28 42 38 Operating profit (EBIT) 22,446 -13,617 5,114 19,525 3,588 Operating margin, % 14 -13 4 16 4 Net profit for the period 11,789 -16,752 -3,715 9,787 -3,364 Cash flow for the period -8,732 -25,660 14,088 -5,592 22,15 6 12Th E Gr OuP'S S TATEMENTS INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 13
Consolidated Balance Sheet KSEK Note 2026-09-30 2025-09-30 2026-03-31 Intangible assets 4 450,603 424,838 441,111 Tangible fixed assets 3,689 5,457 5,903 financial assets 1 1 1 Inventory 169,033 203,247 200,533 Trade receivables 126,646 91,129 92,744 Other receivables 10,287 22,249 23,837 Cash and bank 52,365 78,261 86,757 Total assets 812,624 825,181 850,887 Equity 262,294 259,996 267,056 Deferred Tax liability 25,894 27,892 28,428 Long-term debt, interest-bearing 345,971 342,424 3 45,173 Short-term debt, interest-bearing 106,521 105,941 103,227 Short-term debt, non interest-bearing 33,924 21,955 36,748 Trade payables 38,019 66,972 70,256 Total equity and liabilities 812,624 825,181 850,887 Consolidated Changes in Equity KSEK Apr – Sept 2026 Apr – Sept 2025 Apr 2025 – Mar 2026 Balance at beginning of period 267,056 221,034 221,034 Warrants 197 738 1,726 Profit for the period -4,963 6,465 12,538 Other comprehensive income 4 3 2 rights issue 0 31,755 31,755 Balance at end of period 262,294 259,996 267,056 13Th E Gr OuP'S S TATEMENTS INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 14
Cash Flow KSEK Jul – Sep 2026 Jul – Sep 2025 Apr – Sep 2026 Apr – Sep 2025 Apr 2025 – Mar 2026 Operating profit (EBIT) 22,446 3,588 8,830 24,048 48,682 Interest paid -7,598 -7, 823 -15,079 -15,899 -30,477 Adjustment for items not included in cash flow 7,4 42 5,361 15,155 10,718 23,091 Ta xes 0 0 0 0 0 Cash flow from operations before changes in working capital 22,290 1,126 8,906 18,867 41,300 Changes in inventory 29,823 -26,508 31,501 -24,213 -21,500 Changes in current receivables -32,19 4 24,581 -20,351 25,444 22,240 Changes in current liabilities -14,716 2,135 -25,14 8 -21,968 -13,678 Sum changes in working capital -17,0 87 208 -13,999 -20,738 -12,939 Cash flow from operations 5,203 1,334 -5,092 -1,871 28,361 Acquisitions of intangible non-current assets -8,340 -9,652 -24,566 -33,228 -61,797 Acquisitions of tangible non-current assets 0 471 0 -4,916 -5,444 Cash flow from investment activities -8,340 -9,181 -24,566 -3 8 ,14 4 - 67,241 rights issue 0 31,755 0 31,755 31,755 raising of loans 1,025 1,082 2,129 7,520 12,610 Amortization of loans -6,812 -3,110 -7,054 -2,680 -73 Warrants program 197 738 197 738 1,726 Amortization, leasing debts -4 -462 -6 4,981 -2,782 Cash flow from financing activities -5,595 30,003 -4,734 35,876 43,237 TOTAL CASH FLOW DURING PERIOD -8,732 22,156 -34,392 - 4 ,139 4,357 Cash / cash equivalents at beginning of period 61,097 5 6 ,10 6 86,757 82,400 82,400 Cash / cash equivalents at end of period 52,365 78,261 52,365 78,261 86,757 14Th E Gr OuP'S S TATEMENTS INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 15
Parent Company Profit and Loss Statement KSEK Jul – Sep 2026 Jul – Sep 2025 Apr – Sep 2026 Apr – Sep 2025 Apr 2025 – mar 2026 Net sales 157,220 86,380 26 4 ,125 193,591 432,650 Cost of goods sold -100,958 -53,966 -190,028 -115,016 -269,798 Gross profit 56,262 32,414 74,096 78,575 162,852 Gross margin 36% 38% 28% 41% 38% Sales and marketing expenses -24,680 -19,768 -46,390 -37,345 -80,377 Administration expenses -4,852 -4,658 -10,764 -10,915 -22,588 r&D expenses -4,488 -4,497 -8,757 -7,323 -14,308 Other operating income 530 100 1,061 1,095 3,095 Operating profit (EBIT) 22,772 3,590 9,245 24,087 48,674 Other financial and interest income 2 0 3 1 3 Interest expenses and similar expenses -7,538 -7,769 -14,947 -15,785 -30,243 Profit before tax 15,236 - 4 ,179 -5,699 8,303 18,434 Appropriations 0 0 0 0 -15,000 Ta x -3,057 871 1,289 -1,68 4 -2,578 NET PROFIT FOR THE PERIOD 12,179 -3,308 -4,409 6,619 856 15PArENT COMPANY S TATEMENTS INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 16
Balance Sheet KSEK 2026-09-30 2025-09-30 2026-03-31 Intangible assets 273,193 237,767 258,870 Tangible fixed assets 378 5 41 459 financial assets 391 391 391 Inventory 169,008 203,203 200,494 Trade receivables 126,645 91,132 92,742 Other receivables 187, 837 20 8 ,147 205,246 Cash and bank 51,19 4 7 8 ,102 86,361 Total assets 808,647 819,282 844,563 Equity 152,822 161,810 157,035 Appropriations 138,000 123,000 138,000 Long-term debt, interest-bearing 344,535 340,436 342,486 Short-term debt, interest-bearing 104,551 107,935 111,267 Short-term debt, non interest-bearing 31,120 19,129 25,498 Trade payables 37,619 66,972 70,278 Total equity and liabilities 808,647 819,282 844,563 16PArENT COMPANY S TATEMENTS INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 17
Notes NOTE 1 Accounting and Valuation Policies The Group applies International Financial Reporting Standards (IFRS), as adopted by the EU. This interim report has been prepared in accordance with IAS 34 Interim Financial Reporting; the Annual Accounts Act and the Nasdaq Stockholm Rule Book for Issuers. Disclosures in accordance with IAS 34 p. 16A appear not only in the financial statements and their accompanying notes but also in other parts of the interim report. For the Group, the same accounting policies as those adopted for this report are described on pages 55-60 of the company’s Annual Report and Consolidated Financial Statement for 2025/2026. The company has loans with variable interest rates and thus the fair value is deemed to be in line with the book value. The parent company applies the Annual Accounts Act and the Swedish Financial Reporting Board recommendation RFR 2 Accounting for Legal Entities. NOTE 2 Segment Reporting EQL Pharma’s operations only comprise one operating segment; generics for prescription pharmacy sales and hospital sales, and therefore reference is made to the income statement and balance sheet regarding operating segment reporting. NOTE 3 Allocation of Sales Net sales divided in geographical markets KSEK Jul – Sep 2026 Jul – Sep 2025 Apr – Sep 2026 Apr – Sep 2025 Apr 2025 – Mar 2026 Sweden 38,905 31,676 68,866 65,18 6 144,661 Other Scandinavia 68,850 27,96 8 114,007 77,0 8 8 196,010 Other Europe 47,985 26,735 79,409 50,776 91,155 Outside Europe 1,483 0 1,849 543 835 Total 157,223 86,378 26 4 ,131 193,593 432,661 NOTE 4 Intangible Fixed Assets KSEK Jul – Sep 2026 Jul – Sep 2025 Apr – Sep 2026 Apr – Sep 2025 Apr 2025 – Mar 2026 Opening accumulated cost 526,447 473,719 510,974 45 0,142 45 0,142 Investments for the period 8,340 9,652 24,566 33,228 61,797 Write-down for the period -754 -965 Closing accumulated cost 534,786 483,371 534,786 483,371 510,974 Opening accumulated depreciation -76,783 -53,214 -69,864 -47, 8 96 -47, 8 96 Depreciation for the period -7,4 01 -5,319 -14,320 -10,637 -21,968 Closing accumulated depreciation - 8 4 ,183 -58,533 - 8 4 ,183 -58,533 -69,864 Total intangible fixed assets 450,603 424,838 450,603 424,838 4 41,110 The intangible fixed assets amounted to SEK 450,6 (424,8) million on the balance sheet date. Intan - gible assets are reported at the cost of acquisition minus accumulated depreciation and any write- downs. The useful life is reviewed at each accounting year-end. Ongoing development projects are tested for impairment at least annually. For the recently acquired product portfolio from Medilink, the useful life has been estimated at 20 years and the products are depreciated on a straight-line basis at 5% per year. 17NOTES INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 18
NOTE 5 Transactions with Related Parties The nature and extent of related party transactions are described in the group’s Annual Report and Consolidated Financial Statement for 2025/26. Transactions with related parties arise in the day-to-day operations and are based on com - mercial terms and market prices. In addition to customary transactions between group companies and remuneration to management and the board, the following transactions with related parties have taken place during the period: Transactions with Cadila Pharmaceuticals Ltd regarding goods purchases and development costs have taken place with SEK 24.9 (11.9) million during the period April to September. Warrants were granted to a key employee at EQL Pharma during the quarter. See Note 6. NOTE 6 Share Option Programmes During the period April to September 2026, the company has allocated 100 000 new warrants to the key executive. The warrants have been issued to the fair market value of the warrants at the time of subscrip - tion, which was be determined by Optionspartner as independent valuation institute in accordance with the Black & Scholes valuation formula. Subscription price per warrant amounted to SEK 1.97 and cash received amounted to SEK 197.000. Subscription of shares by virtue of the warrants may be effected from and including 17 February 2031 to and including 3 March 2031. Each warrant entitles the right to subscribe for one new share in the company at a subscription price per share corresponding to 200 per cent of the volume weighted average price according to Nasdaq Stockholm’s official price list for shares in the company during the ten trading days that follows immediately after the publication of the company’s interim report for April – June 2026. In case all warrants issued in connection with the incentive program are exercised for subscrip - tion of new shares, a total of 100,000 new shares will be issued, which corresponds to a dilution of approximately 0.34 per cent of the company’s share capital and votes. The Company has five outstanding incentive programmes in the form of warrant programmes, under which a maximum of 640,000 new shares may be issued. If all warrants issued and held by participants are exercised in full for subscription of shares, a total of 640,000 new shares will be issued, corresponding to a total dilution of approximately 2.44 per cent of the Company’s share capital and voting rights after full dilution. The vesting conditions provide that participants earn the right to the warrants annually over a period of 3.5 years, subject to continued employment during each respective vesting period. As the warrants were issued to participants at market value, it is the Company’s assessment that no social security costs have arisen as a result of the warrant programmes. A description of the complete terms and conditions of the incentive programmes is available on the Company’s website under Investor Relations. NOTE 7 Events after Accounting Period No events after the end of the period. 18NOTES INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 19
Reconciliation tables KPIs, non-IFRS measures The company presents certain financial measures in the interim report which are not defined according to IFRS. The company considers these measures to provide valuable supplementary infor - mation for investors and the company’s management as they enable the assessment of relevant trends. EQL Pharma’s definitions of these measures may differ from other companies’ definitions of the same terms. These financial measures should therefore be seen as a supplement rather than as a replacement for measures defined according to IFRS. Definitions of measures which are not defined according to IFRS and which are not mentioned elsewhere in the interim report are pre - sented below. Reconciliation of these measures is shown in the tables below. Key Performance Indicators Sales growth Net sales divided by net sales corresponding to the period last year. Gross profit Net sales less cost of goods sold. Gross margin Gross profit as a percentage of net sales. Operating profit (EBIT). Earnings before interest and tax. Operating margin (EBIT), %. Operating profit (EBIT) as a percentage of net sales for the period. EBITDA Operating profit (EBIT) before interest, taxes, depreciation and amortization. EBITDA margin % Operating profit (EBIT) adjusted for write-downs and amortization divided by net sales. Pro-forma adjusted EBITDA Pro-forma adjusted EBITDA as if acquired entities had been part of EQL Pharma during the last twelve-month period. Net debt through pro-forma adjusted EBITDA Short-term and long-term liabilities to credit institutions, bond loans less cash and cash equivalents divided by pro forma adjusted EBITDA. R12 EBITDA EBITDA for the rolling twelve-month period. R12 EBITDA margin EBITDA margin for the rolling twelve-month period. Shareholders’ equity per share Shareholders’ equity attributable to Parent Company shareholders divided by the number of outstanding shares at the end of the period. Equity/assets ratio Shareholders’ equity including non-controlling interests as a percentage of total assets. 19rECONCILIATION TABLES KPI S INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 20
SALES GROWTH Jul – Sep 2026 Jul –Sep 2025 Apr –Sep 2026 Apr–Sep 2025 Apr 2025–Mar 2026 A Net sales current period, KSEK 157,223 86,378 26 4 ,131 193,593 432,661 B Net sales last period, KSEK 86,378 85,248 193,593 168,038 373,516 (A-B)/B Sales growth, % 82 1 36 15 16 GROSS PROFIT / GROSS MARGIN Jul – Sep 2026 Jul –Sep 2025 Apr –Sep 2026 Apr–Sep 2025 Apr 2025–Mar 2026 A Net sales, KSEK 157,223 86,378 26 4 ,131 193,593 432,661 B Cost of goods sold, KSEK -100,983 -53,967 -190,055 -115,030 -269,819 A-B Gross profit, KSEK 56,241 32,411 74,076 78,562 162,842 (A-B)/A Gross margin, % 36 38 28 41 38 OPERATING PROFIT (EBIT)/ OPERATING MARGIN Jul – Sep 2026 Jul –Sep 2025 Apr –Sep 2026 Apr–Sep 2025 Apr 2025–Mar 2026 A Operating profit (EBIT), KSEK 22,446 3,588 8,830 24,048 48,686 B Net sales, KSEK 157,223 86,378 26 4 ,131 193,593 432,661 A/B Operating margin (EBIT), % 14 4 3 12 11 EBITDA Jul – Sep 2026 Jul –Sep 2025 Apr –Sep 2026 Apr–Sep 2025 Apr 2025–Mar 2026 A Operating profit (EBIT), KSEK 22,446 3,588 8,830 24,048 48,686 B Write-downs and amortization, KSEK 7,4 42 5,361 15,155 10,718 23,095 A+B EBITDA, KSEK 29,888 8,949 23,985 34,766 71,782 EBITDA MARGIN, % Jul – Sep 2026 Jul –Sep 2025 Apr –Sep 2026 Apr–Sep 2025 Apr 2025–Mar 2026 A Operating profit (EBIT) adjusted for write- downs and amortization, KSEK 29,888 8,949 23,985 34,766 71,782 B Net sales, KSEK 157,223 86,378 26 4 ,131 193,593 432,661 A/B EBITDA margin, % 19 10 9 18 17 20rECONCILIATION TABLES KPI S INTERIM REPORT , APRIL – SEPTEMBER 2026
Page 21
NET DEBT THROUGH PRO-FORMA ADJUSTED EBITDA* Oct 2025 – Sep 2026 Jul –Sep 2025 Apr –Sep 2026 Apr–Sep 2025 Apr 2025–Mar 2026 A EBITDA, KSEK 6 0,941 N/A N/A N/A 71,782 B EBITDA required to complete LTM period prior to acquisition, KSEK N/A N/A N/A N/A N/A A+B Pro-forma adjusted EBITDA, KSEK 60,941 N/A N/A N/A 71,782 B Interest-bearing net debt, KSEK 4 0 0,127 N/A N/A N/A 356,056 B/A Interest-bearing net debt through pro-for - ma adjusted EBITDA, times 6,57 N/A N/A N/A 4,96 PRO-FORMA ADJUSTED EBITDA MARGIN, %* Oct 2025 – Sep 2026 Jul –Sep 2025 Apr –Sep 2026 Apr–Sep 2025 Apr 2025–Mar 2026 A Pro-forma adjusted EBITDA, KSEK 6 0,941 N/A N/A N/A 71,782 B Net sales, KSEK 503, 199 N/A N/A N/A 432,661 A/B Pro-forma adjusted EBITDA margin, % 12 N/A N/A N/A 17 SHAREHOLDERS’ EQUITY PER SHARE Jul – Sep 2026 Jul –Sep 2025 Apr –Sep 2026 Apr–Sep 2025 Apr 2025–Mar 2026 A Profit/loss for the period, KSEK 11,789 -3,364 -4,963 6,465 12,538 B Number of shares 256,300 245,432 264,675 240,515 244,045 A/B Net earnings per share, % 5 -1 -2 3 5 EQUITY-ASSET RATIO Jul – Sep 2026 Jul –Sep 2025 Apr –Sep 2026 Apr–Sep 2025 Apr 2025–Mar 2026 A Equity, KSEK 262,294 259,996 262,294 259,996 267,056 B Balance sheet total, KSEK 812,624 825,181 812,624 825,181 850,887 A/B Equity ratio, % 32 32 32 32 31 * Pro-forma adjusted EBITDA based on the product portfolio acquired by Medilink having been part of EQL Pharma for the twelve-month period ended September 30, 2026, and with assumptions regarding operating costs presented in connection with the signing of the asset transfer agreement on December 10, 2024. 21rECONCILIATION TABLES KPI S INTERIM REPORT , APRIL – SEPTEMBER 2026